Long Term Safety Study of Orfadin Treatment in HT-1 Patients in Standard Clinical Care

NCT02320084 · clinicaltrials.gov ↗

COMPLETED

Status

315

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Tyrosinemia, Type I

Interventions

DRUG: Nitisinone

Sponsor

Swedish Orphan Biovitrum